Five New Genetic Variants Linked With Glioma Identified
the ONA take:
Five new genetic variants associated with glioma have been identified in the biggest ever study of DNA in patients within this population, according to a study published in Nature Communications.
Richard Houlston, MD, PhD, of The Institute of Cancer Research and an international team analyzed DNA from more than 5,637 patients with glioma from Europe, the United States, and Canada, and compared them with 9,158 patients without the disease.
Each variant they found was a one-letter difference in the DNA code that was associated with an increased risk of glioma in those who have it, thus bringing the total number of genetic variants linked to glioma to 12.
One variant in particular was linked with a 23% increased risk of glioblastoma, an aggressive form of glioma with an average survival of 10 to 15 months after diagnosis.
“We believe our study is the largest ever conducted of the genetics of glioma – the most common form of brain cancer – and it provides firm evidence that susceptibility to the disease is in part inherited,” Houlston said.
Five new genetic variants associated with glioma have been identified in the biggest ever study of DNA in patients within this population.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|